MDGL Earnings Madrigal Pharmaceuticals, Inc.
Reported EPS, revenue and net income by fiscal period (SEC EDGAR) — quarterly and annual. Full financials → Chart & overview → Latest filing
Annual results
EPS
Revenue
Net income
Quarterly results
EPS
Revenue
Net income
Reported EPS history
1–31 of 31
| Q2 2026 | 2026-06-30 | -1.99 | 2026-07-30 | 10-Q |
| Q1 2026 | 2026-03-31 | -3.25 | 2026-05-06 | 10-Q |
| Q4 2025 (derived) | 2025-12-31 | -2.03 | 2026-02-19 | 10-K |
| FY 2025 | 2025-12-31 | -10.15 | 2026-02-19 | 10-K |
| Q3 2025 | 2025-09-30 | -4.01 | 2025-11-04 | 10-Q |
| Q2 2025 | 2025-06-30 | -1.50 | 2025-08-05 | 10-Q |
| Q1 2025 | 2025-03-31 | -2.61 | 2025-05-01 | 10-Q |
| Q4 2024 (derived) | 2024-12-31 | -1.79 | 2025-02-26 | 10-K |
| FY 2024 | 2024-12-31 | -17.31 | 2025-02-26 | 10-K |
| Q3 2024 | 2024-09-30 | -3.94 | 2024-10-31 | 10-Q |
| Q2 2024 | 2024-06-30 | -5.68 | 2024-08-07 | 10-Q |
| Q1 2024 | 2024-03-31 | -5.90 | 2024-05-07 | 10-Q |
| Q4 2023 | 2023-12-31 | -5.68 | 2024-02-28 | 10-K |
| FY 2023 | 2023-12-31 | -17.33 | 2024-02-28 | 10-K |
| Q3 2023 | 2023-09-30 | -4.27 | 2023-11-06 | 10-Q |
| Q2 2023 | 2023-06-30 | -3.75 | 2023-08-08 | 10-Q |
| Q1 2023 | 2023-03-31 | -3.38 | 2023-05-09 | 10-Q |
| Q4 2022 | 2022-12-31 | -4.98 | 2023-02-23 | 10-K |
| FY 2022 | 2022-12-31 | -17.23 | 2023-02-23 | 10-K |
| Q3 2022 | 2022-09-30 | -4.75 | 2022-11-03 | 10-Q |
| Q2 2022 | 2022-06-30 | -4.14 | 2022-08-04 | 10-Q |
| Q1 2022 | 2022-03-31 | -3.36 | — | — |
| Q4 2021 | 2021-12-31 | -3.78 | — | — |
| FY 2021 | 2021-12-31 | -14.63 | — | — |
| Q3 2021 | 2021-09-30 | -3.79 | — | — |
| Q2 2021 | 2021-06-30 | -3.72 | — | — |
| Q1 2021 | 2021-03-31 | -3.32 | — | — |
| FY 2020 | 2020-12-31 | -13.09 | — | — |
| FY 2011 | 2011-12-31 | -1.00 | 2012-02-22 | 10-K |
| FY 2010 | 2010-12-31 | -0.93 | — | — |
| FY 2009 | 2009-12-31 | 2.32 | — | — |
Source: SEC EDGAR / XBRL (reported actuals; no consensus estimates). Some issuers (e.g. mortgage REITs, banks) don't report a conventional revenue line, so those charts may be omitted. Q4 EPS marked "derived" is computed as the fiscal-year EPS minus Q1–Q3 (10-Ks report only the annual figure); EPS is not strictly additive across quarters, so it can differ by a cent or two from the issuer's own Q4. A period with no "Reported" date is known only from a later filing's prior-year comparative. Informational only — not financial advice.